Literature DB >> 12174894

Folate receptor targeted delivery of liposomal daunorubicin into tumor cells.

Sandy Ni1, Stacy M Stephenson, Robert J Lee.   

Abstract

BACKGROUND: The folate receptor (FR) is amplified in a wide variety of human tumors. Thus, targeting cytotoxic therapies to FR is a promising strategy for chemotherapy.
MATERIALS AND METHODS: FR-targeted liposomal daunorubicin (f-L-DNR) was compared to non-targeted liposomal DNR (L-DNR) for cellular uptake and cytotoxicity in FR-expressing cells. Liposomal DNR retention was evaluated for liposomes loaded with either sodium citrate or ammonium sulfate as the trapping agent. The cellular uptake of liposomal DNR was determined by flow cytometry and fluorometry measurements while cytotoxicity was determined by the 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.
RESULTS: Liposomal DNR retention was superior for liposomes prepared using ammonium sulfate. Cellular uptake of f-L-DNR in KB oral carcinoma cells, Chinese hamster ovary (CHO-FR-beta), and KG-1 human acute myelogenous leukemia cells were 9.4, 40, and 4,6-fold higher than non-targeted L-DNR, respectively. The cytotoxicity of f-L-DNR in KB and CHO-FR-beta cells was 18 times and 49 times higher than L-DNR, respectively. Both cellular uptake and cytotoxicity of f-L-DNR could be inhibited by 1 mM folic acid.
CONCLUSION: FR-mediated delivery of liposomal DNR to FR-expressing cells increases DNR cellular uptake and cytotoxicity. Therefore, therapeutic evaluation in relevant animal models is warranted.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12174894

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  12 in total

Review 1.  LFA-1 on leukemic cells as a target for therapy or drug delivery.

Authors:  Rungsinee Phongpradist; Chuda Chittasupho; Siriporn Okonogi; Teruna Siahaan; Songyot Anuchapreeda; Chadarat Ampasavate; Cory Berkland
Journal:  Curr Pharm Des       Date:  2010-07       Impact factor: 3.116

2.  Advances of cancer therapy by nanotechnology.

Authors:  Xu Wang; Yiqing Wang; Zhuo Georgia Chen; Dong M Shin
Journal:  Cancer Res Treat       Date:  2009-03-31       Impact factor: 4.679

Review 3.  Nitric oxide release: part II. Therapeutic applications.

Authors:  Alexis W Carpenter; Mark H Schoenfisch
Journal:  Chem Soc Rev       Date:  2012-02-24       Impact factor: 54.564

4.  Fabrication and functional characterization of goldnanoconjugates for potential application in ovarian cancer.

Authors:  Chitta Ranjan Patra; Resham Bhattacharya; Priyabrata Mukherjee
Journal:  J Mater Chem       Date:  2010-01-01

5.  HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors.

Authors:  Xu Wang; Jun Li; Yiqing Wang; Kwang Jae Cho; Gloria Kim; Ada Gjyrezi; Lydia Koenig; Paraskevi Giannakakou; Hyung Ju C Shin; Mourad Tighiouart; Shuming Nie; Zhuo Georgia Chen; Dong M Shin
Journal:  ACS Nano       Date:  2009-10-27       Impact factor: 15.881

6.  Cellular uptake of electron paramagnetic resonance imaging probes through endocytosis of liposomes.

Authors:  Scott R Burks; Eugene D Barth; Howard J Halpern; Gerald M Rosen; Joseph P Y Kao
Journal:  Biochim Biophys Acta       Date:  2009-08-25

Review 7.  Cancer active targeting by nanoparticles: a comprehensive review of literature.

Authors:  Remon Bazak; Mohamad Houri; Samar El Achy; Serag Kamel; Tamer Refaat
Journal:  J Cancer Res Clin Oncol       Date:  2014-07-09       Impact factor: 4.553

Review 8.  Targeted pharmaceutical nanocarriers for cancer therapy and imaging.

Authors:  Vladimir P Torchilin
Journal:  AAPS J       Date:  2007-05-11       Impact factor: 4.009

9.  Biodistribution characteristics of galactosylated emulsions and incorporated probucol for hepatocyte-selective targeting of lipophilic drugs in mice.

Authors:  Emi Ishida; Chittima Managit; Shigeru Kawakami; Makiya Nishikawa; Fumiyoshi Yamashita; Mitsuru Hashida
Journal:  Pharm Res       Date:  2004-06       Impact factor: 4.200

10.  Targeting receptors, transporters and site of absorption to improve oral drug delivery.

Authors:  J H Hamman; P H Demana; E I Olivier
Journal:  Drug Target Insights       Date:  2007-03-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.